Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024998 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01024998 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 19 participants.
The verdict
NCT01024998, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
Interventions
- BIOLOGICAL AAV2-sFLT01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-01-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01024998
The ClinicalTrials.gov registry entry for NCT01024998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AAV2-sFLT01 is the first listed.
NCT01024998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01024998 about?
NCT01024998 is a clinical study titled "Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)". This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
What is the current status of trial NCT01024998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2010-01-11. Estimated completion is 2018-07.
What interventions are being tested in trial NCT01024998?
The interventions under investigation include: AAV2-sFLT01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01024998?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.